SGLT1 Inhibitors
1 drugsAbout SGLT1
SGLT1 (sodium-glucose cotransporter 1) is a membrane protein that facilitates glucose and galactose absorption in the small intestine and kidney.
SGLT1 is an emerging drug target, particularly in cardiovascular disease, but currently lacks genetic evidence linking it to specific diseases.
INPEFA is the only FDA-approved drug targeting SGLT1, developed by LEXICON PHARMS INC for cardiovascular indications as a small molecule.
Top SGLT1 Drugs
LEXICON PHARMS INC is the only company with an approved SGLT1-targeting drug.
The lack of competitors suggests a high barrier to entry or an unvalidated market, requiring careful risk assessment.
SGLT1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SGLT1, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing SGLT1-targeting therapies.
SGLT1 Clinical Trials 48 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SGLT1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 13 | 0 | 1 | 100% |
| Phase 2 | 11 | 4 | 1 | 6 | 80% |
| Phase 3 | 20 | 11 | 5 | 4 | 69% |
| Phase 4 | 3 | 2 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SGLT1 Drug Approval Timeline (2023 - 2023)
The first and only SGLT1-targeting drug, INPEFA, was approved in 2023.
Recent approval suggests growing interest, but further approvals are needed to confirm sustained therapeutic value.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SGLT1. A trial counts if an approved drug acting on SGLT1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.